Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Access here alternative investment news about Ariad's $5.2B Sale To Takeda Nets $260M Windfall For Hedge Fund
Hedge Funds

Ariad's $5.2B Sale To Takeda Nets $260M Windfall For Hedge Fund

by forbes.com posted 1year ago 821 views
<p>Takeda&rsquo;s $5.2 billion takeover of Ariad Pharmaceuticals is turning into a major payday for a weighty but unheralded investor in the drug sector. Sarissa Capital, run by Carl Icahn prot&eacute;g&eacute; Alex Denner, stands to make $260 million on Monday&rsquo;s deal.</p> <p>Ariad, which sells a $199,000 a year treatment for blood clots called Iclusig, is being taken over by Takeda for $24 a share, or a 75% premium to its&nbsp;Friday closing price. But that eye-popping takeover premium only hints at Sarissa Capital&rsquo;s Ariad payday.</p>